Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Metadata
Title
Mechanisms of immune-deposit formation and the mediation of immune renal injury
Authors
Masaomi Nangaku
William G. Couser
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Clinical and Experimental Nephrology / Issue 3/2005
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-005-0357-8

Other articles of this Issue 3/2005

Clinical and Experimental Nephrology 3/2005 Go to the issue

ORIGINAL ARTICLE

Significance of screening for Fabry disease among male dialysis patients

ORIGINAL ARTICLE

Comparison of markers of circulating blood volume in hemodialysis patients

CASE REPORT

Hypocalcemia due to tubular dysfunction in a patient with holoprosencephaly

CASE REPORT

Fibrillary glomerulonephritis associated with monoclonal gammopathy of undetermined significance showing lambda-type Bence Jones protein

ORIGINAL ARTICLE

Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients

CASE REPORT

Efficacy of biventricular pacing for dialysis-related hypotension due to idiopathic dilated cardiomyopathy

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits